Alphatec Holdings, Inc. (NASDAQ:ATEC) COO Scott Lish Sells 23,183 Shares

Alphatec Holdings, Inc. (NASDAQ:ATEC) COO Scott Lish sold 23,183 shares of Alphatec stock in a transaction that occurred on Thursday, February 27th. The stock was sold at an average price of $12.03, for a total value of $278,891.49. Following the completion of the transaction, the chief operating officer now directly owns 844,494 shares in the company, valued at $10,159,262.82. This trade represents a 2.67 % decrease in their ownership of the stock. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through this link.

Scott Lish also recently made the following trade(s):

• On Thursday, February 6th, Scott Lish sold 27,453 shares of Alphatec stock. The shares were sold at an average price of $11.49, for a total transaction of $315,434.97.

Alphatec Stock Performance

Shares of Alphatec stock opened at $12.53 on Friday. The business has a fifty day simple moving average of $10.70 and a two-hundred day simple moving average of $8.42. The firm has a market capitalization of $1.78 billion, a P/E ratio of -9.79 and a beta of 1.43. The company has a current ratio of 2.32, a quick ratio of 1.15 and a debt-to-equity ratio of 30.21. Alphatec Holdings, Inc. has a 12 month low of $4.88 and a 12 month high of $14.88.

Alphatec (NASDAQ:ATEC) last posted its quarterly earnings data on Wednesday, February 26th. The medical technology company reported ($0.23) EPS for the quarter, missing the consensus estimate of ($0.19) by ($0.04). The business had revenue of $176.79 million for the quarter, compared to the consensus estimate of $172.74 million. Alphatec had a negative return on equity of 541.39% and a negative net margin of 31.06%. On average, equities analysts forecast that Alphatec Holdings, Inc. will post -1.08 earnings per share for the current fiscal year.

Analysts Set New Price Targets

A number of research analysts recently issued reports on the company. StockNews.com upgraded Alphatec from a “sell” rating to a “hold” rating in a report on Friday. Needham & Company LLC reissued a “buy” rating and set a $16.00 target price on shares of Alphatec in a research note on Thursday. HC Wainwright reaffirmed a “buy” rating and issued a $20.00 price target on shares of Alphatec in a research note on Tuesday, January 14th. Barclays boosted their price objective on shares of Alphatec from $20.00 to $21.00 and gave the company an “overweight” rating in a research report on Wednesday, January 22nd. Finally, Piper Sandler raised their target price on shares of Alphatec from $12.00 to $13.00 and gave the stock an “overweight” rating in a research report on Thursday. Two equities research analysts have rated the stock with a hold rating and eight have given a buy rating to the stock. According to data from MarketBeat, Alphatec currently has an average rating of “Moderate Buy” and an average target price of $17.67.

Institutional Trading of Alphatec

Hedge funds and other institutional investors have recently made changes to their positions in the stock. Lido Advisors LLC boosted its holdings in Alphatec by 8.4% in the fourth quarter. Lido Advisors LLC now owns 12,247 shares of the medical technology company’s stock worth $112,000 after acquiring an additional 953 shares in the last quarter. PNC Financial Services Group Inc. boosted its stake in Alphatec by 0.4% in the 4th quarter. PNC Financial Services Group Inc. now owns 312,954 shares of the medical technology company’s stock worth $2,873,000 after purchasing an additional 1,120 shares in the last quarter. Comerica Bank boosted its stake in Alphatec by 66.8% in the 4th quarter. Comerica Bank now owns 3,116 shares of the medical technology company’s stock worth $29,000 after purchasing an additional 1,248 shares in the last quarter. Summit Investment Advisors Inc. grew its position in Alphatec by 14.1% during the 4th quarter. Summit Investment Advisors Inc. now owns 10,890 shares of the medical technology company’s stock valued at $100,000 after purchasing an additional 1,342 shares during the last quarter. Finally, Atria Investments Inc increased its stake in Alphatec by 8.0% during the 3rd quarter. Atria Investments Inc now owns 19,609 shares of the medical technology company’s stock valued at $109,000 after purchasing an additional 1,460 shares in the last quarter. Hedge funds and other institutional investors own 66.35% of the company’s stock.

Alphatec Company Profile

Alphatec Holdings, Inc, a medical technology company, designs, develops, and advances technologies for the surgical treatment of spinal disorders in the United States and internationally. It manufactures and sells implants and instruments through third-party suppliers. The company offers Alpha InformatiX product platform, including EOS imaging system that provides full-body imaging; VEA alignment mobile application, which leverages EOS technology to more quickly quantify alignment parameters on a mobile device; SafeOp Neural InformatiX System that automates electromyographic and somatosensory evoked potential monitoring; and Valence, an intra-operative system that integrates navigation and robotics into spine procedures, as well as Sigma Prone TransPsoas (PTP) Access and PTP Patient Positioning Systems.